Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1982 1
1987 1
1993 1
1998 1
2001 1
2007 2
2008 1
2009 1
2012 1
2013 2
2014 2
2015 1
2016 1
2017 1
2018 1
2019 3
2020 6
2021 4
2022 6
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
CONCLUSIONS: Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline. (Funded by F. Hoffmann-La Roche; GRADUATE I and II ClinicalTrials.gov numb …
CONCLUSIONS: Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 …
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative.
Oldroyd AGS, Callen JP, Chinoy H, Chung L, Fiorentino D, Gordon P, Machado PM, McHugh N, Selva-O'Callaghan A, Schmidt J, Tansley SL, Vleugels RA, Werth VP; International Myositis Assessment and Clinical Studies Group Cancer Screening Expert Group; Aggarwal R. Oldroyd AGS, et al. Nat Rev Rheumatol. 2023 Dec;19(12):805-817. doi: 10.1038/s41584-023-01045-w. Epub 2023 Nov 9. Nat Rev Rheumatol. 2023. PMID: 37945774 Review.
The recommendations also advise consideration of upper or lower gastrointestinal endoscopy, nasoendoscopy and (18)F-FDG PET-CT scanning in specific patient populations. These recommendations are aimed at facilitating earlier IIM-associated cancer detection, especially in t …
The recommendations also advise consideration of upper or lower gastrointestinal endoscopy, nasoendoscopy and (18)F-FDG PET-CT scanni …
Progression and prognosis of interstitial pneumonia with autoimmune features: a longitudinal, prospective, multi-centre study.
Sambataro G, Sambataro D, Spicuzza L, Meloni F, Lorini G, Malatino L, Colaci M, Sebastiani G, Iuliano A, Canofari C, Luppi F, Franco G, Zanini U, Manfredi A, Gozzi F, Sebastiani M, Palmucci S, Cavagna L, Vancheri C. Sambataro G, et al. Clin Exp Rheumatol. 2023 May;41(5):1140-1148. doi: 10.55563/clinexprheumatol/lycdca. Epub 2022 Oct 3. Clin Exp Rheumatol. 2023. PMID: 36189910 Free article.
Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study.
Doskaliuk B, Ravichandran N, Sen P, Day J, Joshi M, Nune A, Nikiphorou E, Saha S, Tan AL, Shinjo SK, Ziade N, Velikova T, Milchert M, Jagtap K, Parodis I, Gracia-Ramos AE, Cavagna L, Kuwana M, Knitza J, Chen YM, Makol A, Agarwal V, Patel A, Pauling JD, Wincup C, Barman B, Tehozol EAZ, Serrano JR, La Torre IG, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Goo PA, Shumnalieva R, Hoff LS, Kibbi LE, Halabi H, Vaidya B, Shaharir SS, Hasan ATMT, Dey D, Gutiérrez CET, Caballero-Uribe CV, Lilleker JB, Salim B, Gheita T, Chatterjee T, Distler O, Saavedra MA; COVAD study group; Chinoy H, Agarwal V, Aggarwal R, Gupta L. Doskaliuk B, et al. Rheumatol Int. 2023 Sep;43(9):1651-1664. doi: 10.1007/s00296-023-05345-y. Epub 2023 Jun 23. Rheumatol Int. 2023. PMID: 37351634 Free PMC article.
Telemedicine in rheumatology: a reliable approach beyond the pandemic.
Cavagna L, Zanframundo G, Codullo V, Pisu MG, Caporali R, Montecucco C. Cavagna L, et al. Rheumatology (Oxford). 2021 Jan 5;60(1):366-370. doi: 10.1093/rheumatology/keaa554. Rheumatology (Oxford). 2021. PMID: 32893293 Free PMC article.
Demographical and occupational factors were also collected, and their influence on the answers has been evaluated by a multivariate analysis. RESULTS: A total of 175 patients answered our survey (M/F = 28/147), with a median age of 62.5 years [interquartile range (IQR) 53- …
Demographical and occupational factors were also collected, and their influence on the answers has been evaluated by a multivariate analysis …
Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer.
Cavagna R, Escremim de Paula F, Sant'Anna D, Santana I, da Silva VD, da Silva ECA, Bacchi CE, Miziara JE, Dias JM, De Marchi P, Leal LF, Reis RM. Cavagna R, et al. JCO Glob Oncol. 2021 Apr;7:639-645. doi: 10.1200/GO.20.00615. JCO Glob Oncol. 2021. PMID: 33956502 Free PMC article. No abstract available.
Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study.
Crisafulli S, Sultana J, Ingrasciotta Y, Addis A, Cananzi P, Cavagna L, Conter V, D'Angelo G, Ferrajolo C, Mantovani L, Pastorello M, Scondotto S, Trifirò G. Crisafulli S, et al. Expert Opin Drug Saf. 2019 Jun;18(6):497-509. doi: 10.1080/14740338.2019.1614165. Epub 2019 May 22. Expert Opin Drug Saf. 2019. PMID: 31059293 Review.
COVAD survey 2 long-term outcomes: unmet need and protocol.
Fazal ZZ, Sen P, Joshi M, Ravichandran N, Lilleker JB, Agarwal V, Kardes S, Kim M, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Selva-O'Callaghan A, Nune A, Knitza J, Kuwana M, Gutiérrez CT, Caballero-Uribe CV, Dey D, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. Fazal ZZ, et al. Rheumatol Int. 2022 Dec;42(12):2151-2158. doi: 10.1007/s00296-022-05157-6. Epub 2022 Aug 14. Rheumatol Int. 2022. PMID: 35964271 Free PMC article.
Effects in man and rabbits of inhalation of cotton dust or extracts and purified endotoxins.
Cavagna G, Foà V, Vigliani EC. Cavagna G, et al. Br J Ind Med. 1969 Oct;26(4):314-21. doi: 10.1136/oem.26.4.314. Br J Ind Med. 1969. PMID: 4899667 Free PMC article.
Cavagna, G., Foa V., and Vigliani, E. C. (1969).Brit. J. industr. ...The effect of the inhalation by aerosol of purified Escherichia coli endotoxin on F.E.V.(1.0) and F.V.C. was studied in normal subjects and in patients with chronic bronchitis. ...
Cavagna, G., Foa V., and Vigliani, E. C. (1969).Brit. J. industr. ...The effect of the inhalation by aerosol of purified Escherichia …
40 results